Responses
Clinical and epidemiological research
Concise report
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
Compose a Response to This Article
Other responses
No responses have been published for this article.